Abstract: TH-PO1077
The Economic Burden of CKD Progression Among Patients with and Without Major Adverse Cardiac Events (MACE) in the US
Session Information
- CKD: Epidemiology, Risk Factors, Prevention - I
October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Okoro, Tony, GlaxoSmithKline, Collegeville, Pennsylvania, United States
- Chen, Yong, GlaxoSmithKline, Collegeville, Pennsylvania, United States
- Casillas, Linda, GlaxoSmithKline, Collegeville, Pennsylvania, United States
- Zheng, Shan, GlaxoSmithKline, Collegeville, Pennsylvania, United States
- Parks, Daniel C., GlaxoSmithKline, Collegeville, Pennsylvania, United States
- Kovesdy, Csaba P., University of Tennessee Health Science Center, Memphis, Tennessee, United States
Background
Little is known about the costs of CKD progression among patients with cardiovascular disease. The objective of this study was to assess the economic burden of CKD progression among CKD patients with and without MACE.
Methods
Optum claims data were used to identify patients with baseline non-dialysis dependent CKD (stages 3a, 3b, 4 and 5) in 2013 using estimated glomerular filtration rate (eGFR) based on the Kidney Disease Outcomes Quality Initiative (KDOQI) diagnosis criteria. Patients were followed through 6/30/2017 to assess CKD progression defined as worsening CKD stage from baseline. Annualized all-cause costs were assessed between patients with and without defined CKD stage progression and then stratified by the presence or absence of follow-up MACE.
Results
57,597 CKD patients were identified in 2013, among which 35,975, 16,982, 4,340 and 299 had CKD stages 3a, 3b, 4 and 5, respectively. Among those without MACE (n=47,004), mean annualized all-cause costs increased from stage 3a ($8,398) to 5 ($12,711) in those without stage progression and from stage3a ($12,062) to 5 ($79,093) in those with stage progression. Mean annualized all-cause costs among patients with ≥1 MACE (n=10,593) were from $35,924 for stage3a to $42,479 for stage5 without stage progression and from $40,687 (stage 3a) to $97,013 (stage 5) with stage progression. Overall, CKD progression costs for the entire cohort increased from stage3a ($6,010) to stage5 ($66,737) (P for trend < 0.001). The trends were consistent among those with and without MACE.
Conclusion
Progression of CKD increases the economic burden in patients regardless of MACE status but healthcare costs are higher in those with MACE compared to those without MACE. Preventing renal function decline could reduce economic burden seen in patients with advanced CKD stages and MACE.
Funding
- Commercial Support –